Find Academic Supervisors

• Molecular Biology
• Transcriptomics
• HPV-Related Cancers
• +3 more

Dr. Hiroko Matsunaga is a Senior Researcher (Research Associate Professor) at Waseda University's Research Organization for Nano & Life Innovation since 2025. She previously held positions at Waseda University (1993-2018), Central Research Laboratory at Hitachi, Ltd. (1993-2018), and was a Visiting Scholar at Iowa State University (2001-2003) and Aika State University (1994-1995). She earned her Doctor of Science from Osaka Prefecture University in 1993. Education: PhD (Science) from Osaka Prefecture University (1989-1993) Her research focuses on molecular biology, particularly in single-cell and microtissue transcriptomics, HPV18-related cervical cancers, and spatial gene expression analysis in diseases like Alzheimer's and Marfan syndrome. She has pioneered methods for spatial transcriptomics using FFPE tissues and developed tools for precision medicine in rare cancers. Recent publications highlight her work in spatial transcriptomics, HPV18 infection mechanisms, and applications of organoid models. Her methodologies integrate advanced biotechnology with bioinformatics to address tumor heterogeneity, viral carcinogenesis, and cardiovascular pathologies. She contributes to grants like the JSPS-funded project on personalized lung cancer medicine. She has co-authored patents in nucleic acid analysis, cell collection systems, and gene detection methods. Collaborations span institutions like Osaka University, Iowa State University, and Aika State University.

• Amelogenesis Imperfecta
• Inherited Retinal Dystrophies
• Gene Editing
• +6 more

Dr Claire E. L. Smith is a Lecturer in Biomineralisation in Oral Health at the School of Medicine, University of Leeds. She co-leads the Amelogenesis Research Group and is a member of the Biomineralisation Group and the Leeds Centre for Disease Models. Her research focuses on Amelogenesis Imperfecta (AI) and its molecular mechanisms Inherited retinal dystrophies (IRDs) through the UK consortium Ciliopathies affecting kidney function via high-throughput drug screening She utilizes CRISPR-Cas9 gene editing, stem cell models, and advanced sequencing techniques (whole exome, genome, nanopore) to study disease mechanisms and develop therapeutics, including Personalized medicine approaches for AI Drug discovery for polycystic kidney disease Variant curation for NHS diagnostic protocols Scientific awards include Wellcome Trust Institutional Strategic Support funding (2016) Kidney Research UK grant (over £500,000, 2020) She supervises PhD students including Jack Roberts and Georgios Nikolopoulos, and teaches across undergraduate and postgraduate levels. Her work spans collaboration with institutions like University College London, Oxford, and Sheffield.

Daniel Pomeranz KrummelView profile

Associate Professor

• gene expression
• membrane transport
• RNA
• +7 more

Daniel Pomeranz Krummel, PhD, is an Associate Professor in the Department of Neurosurgery at the University of North Carolina at Chapel Hill School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center. His research focuses on improving treatments for malignant brain tumors, both primary and metastatic, with particular emphasis on advanced therapeutic approaches. Dr. Krummel's research interests span multiple disciplines within cancer biology and neuro-oncology, including gene expression , membrane transport , RNA biology , ultrasound technology , drug development , immunotherapy , radiation , and epigenetics . His work integrates molecular biology with innovative engineering approaches to tackle challenging brain tumor cases. Analysis of Dr. Krummel's most recent publications reveals a strong focus on developing advanced models for brain tumor research, particularly glioblastoma. His work combines microfluidics , single-cell analysis , and ultrasound-enhanced delivery systems to overcome barriers in brain tumor treatment. Recent publications also demonstrate his interdisciplinary approach spanning structural biology, cancer therapeutics, and novel drug delivery mechanisms. Life Member, Clare Hall College, Univ. Cambridge, 2008 – Present Research Fellow, Clare Hall College, Univ. Cambridge, 2002 – 2006 Long-term Fellowship, Human Frontier Science Program, 2000 – 2003 Graduate Fellowship, National Institutes of Health (NRSA), 1995 – 1997 CIBA Research Award, 1993 Dr. Krummel collaborates extensively with researchers like Soma Sengupta on brain tumor projects, including the development of ultrasound technology and glioblastoma-on-chip microdevices. His work has received significant funding through prestigious fellowships and awards, indicating strong support for his innovative research directions in neuro-oncology and therapeutic development.

Soma SenguptaView profile

Professor

• Neuro-Oncology
• Brain Tumor Research
• Clinical Trials
• +5 more

Soma Sengupta, MD, PhD, FRCP, FAAN, FANA , is a Professor at the UNC School of Medicine , where she serves as Division Chief of Neuro-Oncology , Vice Chair of Research in the Department of Neurosurgery , and Vice Chair in Neurology. She is a member of the UNC Lineberger Comprehensive Cancer Center and a board-certified neuro-oncologist with a focus on brain tumor treatment and clinical research . Education : MD and PhD from University of Cambridge; Residency at Beth Israel Deaconess (Neurology); Fellowships at Massachusetts General Hospital (Neuro-Oncology) and University of Arizona (Integrative Medicine). Research : Her work bridges clinical trials and lab-based investigations , targeting ion channels and metabolic pathways in brain tumors. She develops novel therapies for glioblastoma and brain metastases, including microfluidic models and phytochemical drug delivery . Scientific Impact : Over 80 publications, including high-profile studies in Nature and Cell , focusing on glioblastoma drug resistance , immune evasion , and personalized treatment platforms . Key projects include the Consortium for Intracranial Metastasis Academic Research (CIMARa) and RNA therapeutic strategies for tumor suppressors. She holds patents for deuterated benzodiazepine analogs in cancer treatment. Awards : Leonard Tow Humanism in Medicine Award (2023) Bye-Fellow, University of Cambridge (2021) Fellowship of the Royal College of Physicians (2020) Clinical Focus : Treats patients at UNC Hospitals Neurology Clinic , specializing in neuro-oncology and integrative medicine for cancer survivors.

• Dendritic Nanosystems
• Biomedical Applications
• Metal Complexes
• +4 more

Jesus Cano Sierra is a Full Professor at the University of Alcalá's Department of Organic Chemistry and Inorganic Chemistry. His research centers on dendritic nanosystems for biomedical applications, including drug delivery, antiviral agents, and cancer therapeutics. He co-leads the Nanosistemas Dendríticos para Aplicaciones Biomédicas group, focusing on carbosilane dendrimers and metal complexes. His work spans multiple domains: Drug Delivery : Designing pH-responsive dendrimers for targeted therapy. Antiviral Research : Developing dendritic systems to inhibit HIV-1. Cancer Therapy : Using ruthenium complexes to disrupt cancer signaling pathways. Environmental Remediation : Creating dendrimer-based nanomaterials for heavy metal removal. He has secured significant funding, including grants from MICINN and UAH, such as PID2020-112924RB-I00 (€145,200) for dendritic nanosystems in infectious diseases. His recent publications emphasize polymerization catalysis, dendritic nanomaterials, and biomedical applications. Awards : Programa I3 Research Incentive Award (2010). Professor Sierra's lab utilizes advanced synthetic chemistry to address biomedical and environmental challenges, with ongoing projects extending through 2025.

Sarah AtkinsonView profile

Senior Lecturer

• Stratified Medicine
• Ophthalmology
• siRNA Therapeutics
• +4 more

Dr. Sarah Atkinson is a Senior Lecturer at Ulster University's School of Biomedical Sciences, where she leads initiatives in stratified medicine and ophthalmology research. She holds a BSc from Queen’s University Belfast and MRes/PhD from Ulster University, with postdoctoral work including a sabbatical at the University of Dundee focusing on siRNA therapies. Her research applies molecular diagnostics and personalized treatments to eye diseases, with emphases on: siRNA-based therapies for corneal dystrophies NLRP3 inflammasome targeting in glaucoma CRISPR/Cas9 applications for mutation-specific disorders Angiogenesis mechanisms in ocular diseases She directs Ulster's Stratified Medicine postgraduate programs and received the Collaborative Award for Teaching Excellence (2024) and Distinguished Fellowship (2023) for educational leadership. Current projects include Alzheimer's-eye biomarker studies and NLRP3 inhibitor development. She leads a research team within the Northern Ireland Centre for Stratified Medicine and supervises PhD candidates in glaucoma therapeutics and molecular ophthalmology.

Xiao HuangView profile

Assistant Professor

• Biomaterials
• Immune Engineering
• Immunotherapy
• +3 more

Xiao Huang is an Assistant Professor at the School of Biomedical Engineering, Science and Health Systems at Drexel University. He received his BS in Biological Sciences from Nanjing Agricultural University (2008), MS in Biochemical Engineering from East China University of Science and Technology (2011), and PhD in Chemistry and Materials from UC Santa Barbara (2016). His research focuses on engineering biomaterials to program immune cell fates for therapeutic applications. Education: PhD in Chemistry and Materials, UC Santa Barbara (2016) MS in Biochemical Engineering, East China University of Science and Technology (2011) BS in Biological Sciences, Nanjing Agricultural University (2008) His research develops innovative platforms using precision materials engineering to control immunotherapies. Projects include: Biomaterial toolkits for CAR-T cell phenotype programming Implantable "recharge stations" for T cell modulation Spatially precise in vitro tumor models to study immune infiltration His work integrates super-resolution imaging, gene editing, and synthetic biology to mimic natural cell-cell communication. Publications span top journals like Nature Nanotechnology and ACS Nano , with co-inventorship on two pending patents in biocompatible materials. Honors: 2022 BWF BioInterfaces Rising Star Award AAI Annual Meeting Abstract Award (2020-2021) UCSF-PBBR Fellowship (2017-2018) Li Foundation Fellowship (2017-2019) Dr. Huang advises graduate students and actively recruits trainees across academic levels. His lab pioneers implantable biomaterial systems and 3D tumor organoids for immune engineering breakthroughs.

• Plant Molecular Biology
• Genetics
• Epigenetics
• +6 more

Dr. Chris Winefield is an Associate Professor in the Department of Wine Food & Molecular Biosciences at Lincoln University's Faculty of Agriculture and Life Sciences in New Zealand. His research focuses on plant molecular biology and genetics, particularly studying transposable elements in crop evolution and epigenetic regulation in response to changing environments. He works extensively with horticultural plant species such as grapevine and hops, investigating key industry issues including seasonal variation in flowering, fruit and flower development, and the development of flavor and aroma biochemistry. Dr. Winefield earned his PhD from the University of Otago and his MSc (Hons) from Waikato University. His academic career includes positions as Senior Lecturer at Lincoln University (2004-2021), Post Doctoral Fellow at the University of York (2001-2004), and Scientist at Crop & Food Research Ltd (1994-2001). His research program utilizes diverse methodologies including de-novo genome sequencing and annotation, whole genome bisulphite sequencing, traditional breeding/genetics, and agronomic assessment of grape and hop populations. A key focus is studying how controlled bursts of transposon activity can be used to develop new germplasm to meet industry challenges. His work addresses significant issues related to climate change, food security, and sustainable agricultural practices, aligning with UN Sustainable Development Goals including Zero Hunger, Quality Education, Responsible Consumption and Production, Climate Action, and Life on Land. Dr. Winefield's publication record demonstrates consistent contributions to plant genomics, epigenetics, and viticulture research. His recent work shows increasing focus on transposable elements, genome regulation, and the molecular basis of traits important to horticultural industries. He has developed expertise in both long-read and short-read sequencing technologies and their application to plant genome analysis. Chairperson Bio-safety committee (2012-present) Member Faculty Agriculture and Life Sciences research committee (2018-present) Dr. Winefield actively supervises postgraduate students, with numerous completed Masters and PhD projects focusing on various aspects of plant genetics, molecular biology, and horticultural science. His laboratory continues to develop innovative approaches to studying plant genome dynamics and their applications to crop improvement.

Henrik FranzykView profile

Associate Professor

• Antimicrobial peptides
• Peptidomimetics
• Drug delivery
• +7 more

Henrik Franzyk is an Associate Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. His research focuses on peptide-based drug design, particularly antimicrobial compounds and drug delivery systems for addressing antibiotic resistance. Dr. Franzyk received his MSc Engineering (Chemistry) in 1991 and PhD (Natural Products Chemistry) in 1993, both from the Technical University of Denmark (DTU). His academic career began with postdoctoral positions at Carlsberg Laboratory (1994-1996) working with Prof. Morten Meldal on peptide chemistry, followed by a postdoc at Colorado State University (1997), and research positions at DTU before joining the University of Copenhagen in 2000. His primary research interests include: SAR studies of peptide-based/peptidomimetic antibacterial compounds as well as potentiators and conjugates of antibiotics Bacterial delivery of antibiotics (including AMPs and antisense PNA oligomers) Improved macromolecular drug delivery (targeting peptides and cationic lipids for nanoparticles with siRNA/mRNA; lipid adjuvants for vaccines) Mechanisms and structural optimization of immunomodulating peptides and peptidomimetics Solid-phase synthesis method development Dr. Franzyk's recent publication record demonstrates a consistent focus on antimicrobial peptides and peptidomimetics with applications against multidrug-resistant bacteria. His work emphasizes structure-activity relationships, particularly how hydrophobicity affects antibacterial activity and selectivity. Many publications explore novel approaches to overcoming resistance through peptide-based antibiotics, efflux pump inhibitors, and bacterial delivery systems, with significant contributions to cyclic lipopeptide antibiotics and peptide/peptoid hybrid oligomers. His research is supported by major grants including: Novo Nordisk Foundation (Center for Peptide-Based Antibiotics - CEPAN) Norwegian Research Council (A platform for development of peptide-based antimicrobials) Danish Research Council (Exploration of efflux pump inhibitor conjugates) European Union funding (SPRINGBOARD and ENABLE projects) Dr. Franzyk actively supervises students at all levels, including current PhD student Johan Storm Jørgensen working on novel cyclic lipopeptide antibiotics. His laboratory, part of the Peptide-based Drug Research group, collaborates extensively with national and international partners including Oslo University Hospital, University of Copenhagen departments, and several European research institutions.

Friederike AdamsView profile

Professor

• Polymer Chemistry
• Nanomedicine
• Drug Delivery Systems
• +5 more

Dr. Friederike Adams is an accomplished researcher at the forefront of polymer chemistry and nanomedicine. She currently serves as an Independent Junior Research Group Leader at the University of Stuttgart and University of Tübingen, and as Deputy Professor at the Technical University of Munich since April 2025. Her research group "Precision Polymers for Pharmaceutics" operates as a joint initiative between the University of Stuttgart and the Schnichels Lab at the Eye Hospital Tübingen. Her research focuses on designing innovative drug delivery systems using sustainable materials, with particular emphasis on intelligent, bio-based and biodegradable polymers. The group specializes in sophisticated polymerization techniques including living-type polymerizations, block copolymerizations, and catalyst design. Key research areas encompass polymer analysis, drug and nucleic acid encapsulation, formulation development, and in vitro evaluation of nanoparticles. Professor Adams' recent publications demonstrate a strong trajectory in sustainable polymer chemistry and nanomedicine applications, particularly in ocular therapeutics. Her work on yttrium-mediated ring-opening polymerization of dihydrocarvide showcases her innovative approach to developing tunable terpene-based polyesters. Publication in Polymer Chemistry Emerging Investigators Series (2025) Wiley poster prize 2024 (with group members) Best oral communication award at IP'24 in Mainz Professor Adams actively supervises multiple PhD, Master's, and Bachelor students, providing them with opportunities to work at the cutting edge of polymer science and nanomedicine. Her research group benefits from substantial funding through the Excellence Strategy of the German Federal and State Governments, supporting their work on precision polymers for pharmaceutical applications. The "Precision Polymers for Pharmaceutics" lab maintains strong collaborative ties with biomedical researchers at the Eye Hospital Tübingen, ensuring their polymer research has direct relevance to therapeutic applications, particularly in ocular drug delivery systems.

• Neurology
• Neurodegenerative Diseases
• Movement Disorders
• +5 more

Professor Günter Höglinger serves as a faculty member in the Department of Neurology at Ludwig Maximilian University of Munich's Faculty of Medicine, based at University Hospital of Munich (Campus Großhadern) and leading the German Center for Vertigo and Balance Disorders (IFB). His research program targets neurodegenerative mechanisms with dual clinical focus: movement disorders (Parkinson's disease, Progressive Supranuclear Palsy, multisystem atrophy) and vestibular pathologies. Key methodologies include molecular therapy development (siRNA), neuroinflammation modeling, and multi-omics integration to identify therapeutic targets. The German Center for Vertigo and Balance Disorders provides specialized clinical and research infrastructure for translational studies. Professor Höglinger's scientific recognition includes the prestigious Heisenberg Professorship from the German Research Foundation (DFG), awarded for his work on Progressive Supranuclear Palsy. His completed DFG projects demonstrate sustained funding success in high-impact areas: Inflammation mechanisms in Parkinson's disease models siRNA therapeutics for tauopathies Multi-omics approaches for multisystem atrophy interventions His research group operates at the intersection of clinical neurology and molecular neuroscience, maintaining active investigation into disease mechanisms while developing novel treatment strategies for debilitating neurodegenerative conditions through the IFB platform.

• Gene Therapy
• Hematology
• Hemostasis
• +4 more

Dr. Qizhen Shi is a Professor in the Department of Pediatrics at the Medical College of Wisconsin and a Senior Investigator at the Blood Research Institute, Versiti Wisconsin. He holds memberships in the Center for Immunology and Center for Microbiome Research, emphasizing interdisciplinary collaboration in hematology and immunology. His research focuses on: Platelet-targeted gene therapy for hemophilia A/B, developing strategies to induce immune tolerance and overcome inhibitory antibodies Factor VIII immunology , investigating T follicular helper cells, CXCL13 signaling, and mechanisms of inhibitor formation Von Willebrand factor biology and its role in platelet adhesion, hemostasis, and thrombus stabilization Hematopoietic stem cell engineering for sustained coagulation factor delivery and phenotypic correction Dr. Shi's 86 publications demonstrate consistent productivity, with recent work (2022-2025) advancing siRNA/nanoparticle therapies, novel conditioning regimens, and mechanistic insights into platelet clearance and immune regulation. His articles frequently appear in high-impact journals like Blood and Nature Communications . He leads research at Versiti's Blood Research Institute and mentors junior faculty, though specific student advisees and lab details are not provided in the source material.

Kate HydeView profile

Associate Professor

• Leukemia
• Acute Myeloid Leukemia
• Hematological Malignancies
• +5 more

Kate Hyde, PhD, is an Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Nebraska Medical Center (UNMC) College of Medicine. She also serves as Associate Director for Shared Resources at the Fred & Pamela Buffett Cancer Center. Her laboratory investigates molecular mechanisms of acute myeloid leukemia (AML), with emphasis on chromosome 16 inversion (Inv(16))-driven AML and the oncogenic fusion protein CBFβ-SMMHC. Education includes: Bachelors of Arts in Biology from Washington University in St. Louis PhD in Cellular and Molecular Biology from University of Wisconsin-Madison Post-doctoral fellowship at National Human Genome Research Institute, NIH Her research integrates: Leukemia and normal blood development pathways Regulation of gene expression in hematological malignancies Development of targeted therapies using mouse models and drug delivery systems She collaborates extensively, including projects with UNMC College of Pharmacy on polymeric CXCR4 inhibitors. Recent publication trends (15 most recent) focus on: Leukemia stem cell persistence mechanisms in bone marrow CXCR4-targeted drug delivery systems Epigenetic regulators (HDAC1) and metabolic dependencies in AML Novel therapeutics like liposomal miR-497-5p/venetoclax combinations RUNX1/CBFβ-SMMHC transcriptional networks Dr. Hyde actively mentors students interested in leukemia research and encourages inquiries about lab opportunities.

• Plant Reproductive Biology
• Epigenetics
• siRNA Biogenesis
• +3 more

Dr. Jiali Zhu serves as a Research Fellow at the Max Planck Institute of Molecular Plant Physiology, where she is embedded in Department 2 under Prof. Köhler's leadership, focusing on Plant Reproductive Biology and Epigenetics. Her research centers on epigenetic mechanisms in plant reproduction, specifically investigating siRNA biogenesis and functional roles during reproductive processes in Arabidopsis thaliana and Capsella rubella . This work bridges plant genetics, molecular epigenetics, and reproductive biology to understand regulatory networks controlling seed development and transgenerational inheritance. No scientific awards were documented in the provided materials. Dr. Zhu operates within Prof. Köhler's specialized research group, contributing to cutting-edge studies on epigenetic regulation in plant reproduction through molecular and genomic approaches.

• Molecular Medicine
• Cancer Biology
• Gene Expression Regulation
• +7 more

Prof. Marija Krstic-Demonacos is a Professor of Molecular Medicine at the University of Salford's School of Science, Engineering & Environment. Previously, she was a Wellcome Trust Fellow and Lecturer at the University of Manchester. She directed the Biomedical Research Centre (2014-2022) and holds a PhD in Endocrinology from UCSF, with postdoctoral training at Glasgow University. Research Interests: Her work explores molecular mechanisms in cancer biology, including stress responses, steroid receptors, tumor suppressor p53, and gene regulation. She focuses on translational applications in leukemia, lung cancer, breast cancer, and mesothelioma using molecular biology, bioinformatics, and clinical data. Recent Publications: Her 2020-2023 articles emphasize cancer biomarkers (e.g., intratumor microbiota in mesothelioma), therapeutic targets (PDIA1 in breast cancer), and resistance mechanisms (glucocorticoid resistance in leukemia). Awards & Recognition: Wellcome Trust Fellowship 3 patents for cancer-related innovations Teaching & Supervision: She leads modules in Pathologies of Human Disease and Novel Therapeutics, developed the MSc Biomedical Science curriculum, and supervises PhD students. Grants include Daiwa Foundation and Mesothelioma UK-BLF funding. Lab Affiliation: She is affiliated with the Biomedical Research Centre, focusing on interdisciplinary cancer research.